References

Ally S, Clair T, Katsaros D, et al. ( 1989 ). Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate. Cancer Res, 49 : 5650 - 5655 . Block GA ( 2000 ). Prevalence and clinical consequences of elevated Ca x P product on hemodialysis patients. Clin Nephrol, 54(4):318-324. Bone Care International, Inc., (1999). Package insert, Hectorolâ„¢ (doxercalciferol) capsules. June 9.

Brown AP, Morrissey RL , Smith AC, Tomaszewski JE , Levine BS ( 2000 ). Comparison of 8 -chloroadenosine (NSC - 354258) and 8 - chloro - cyclic - AMP (NSC - 614491) toxic-ity in dogs. Proc Am Assoc Cancer Res, 41:491 (abstract 3132). Brown AP, Courtney C, Carlson T, Graziano M (2005a). Administration of a MEK inhibitor results in tissue mineralization in the rat due to dysregulation of phosphorus and calcium homeostasis. Toxicologist, 84 ( S - 1 ): 108 (abstract 529). Brown AP, Courtney CL , King LM , Groom SL , Graziano MJ ( 2005b ). Cartilage dys-plasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. Toxicol Pathol, 33(4):449-455. Brown AP, Reindel JF, Grantham L , et al. ( 2006 ). Pharmacologic inhibitors of the MEK-MAP kinase pathway are associated with toxicity to the skin, stomach, intestines, and liver. Proc Am Assoc Cancer Res, 47:308 (abstract 1307). Brown AP, Carlson TCG, Loi CM , Graziano MJ ( 2007 ). Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol, 59 : 671 - 679 .

Chen PS, Terepka AR , Overslaugh C ( 1962 ). Hypercalcemic and hyperphosphatemic actions of dihydrotachysterol, vitamin D2 and Hytakerol (AT-10) in rats and dogs. Endocrinology, 70:815-821.

DeGeorge JJ, Ahn CH, Andrews PA, et al. (1998). Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol, 41:173-185.

Dent P, Grant S ( 2001 ). Pharmacologic interruption of the mitogen - activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res, 7 : 775 - 783 .

Ferreira A , Drueke TB ( 2000 ). Biological markers in the diagnosis of the different forms of renal osteodystrophy. Am J Med Sci, 320 ( 2 ): 85 - 89 .

Friday BB, Adjei AA (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res, 14 ( 2 ): 342 - 346 .

Fu JY, Muller D (1999). Simple, rapid enzyme-linked immunosorbent assay (ELISA) for the determination of rat osteocalcin. Calcif Tissue Int, 64 : 229 - 233 .

Giachelli CM , Jono S, Shioi A , Nishizawa Y, Mori K , Morii H ( 2001 ). Vascular calcification and inorganic phosphate. Am J Kidney Dis, 38(4, Suppl 1):S34-S37.

Grant RA, Gillman T, Hathorn M (1963). Prolonged chemical and histochemical changes associated with widespread calcification of soft tissues following brief calciferol intoxication. Br J Exp Pathol, 44(2):220-232.

Harrington DD, Page EH (1983). Acute vitamin D3 toxicosis in horses: case reports and experimental studies of the comparative toxicity of vitamins D2 and D3. J Am Vet Med Assoc, 182(12):1358-1369.

Haschek WM, Krook L, Kallfelz FA, Pond WG (1978). Vitamin D toxicity, initial site and mode of action. Cornell Vet, 68(3):324-364.

Haura EB, Larson TG, Stella PJ, et al. ( 2007 ). A pilot phase II study of PD - 0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapy, abstract B110.

Hoshino R, Chatani Y, Yamori T, et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase pathway in human tumors. Oncogene, 18: 813 - 822 .

Jost M , Huggett TM , Kari C, Boise LH , Rodeck U ( 2001 ). Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-XL expression through a MEK-dependent pathway. JBiol Chem, 276(9):6320-6326.

Kamio A, Taguchi T, Shiraishi M, Shitama K, Fukushima K, Takebayashi S (1979). Vitamin D sclerosis in rats. Acta Pathol Jpn, 29(4):545-562.

Kanis JA, Russell RGG (1977). Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1a-hydroxylated derivatives. Br Med J, 1:78-81.

Knutson JC, LeVan LW, Valliere CR, Bishop CW (1997). Pharmacokinetics and systemic effect on calcium homeostasis of 1a,25-dihydroxyvitamin D2 in rats. Biochem Pharm, 53 : 829 - 837 .

Long GG (1984). Acute toxicosis in swine associated with excessive dietary intake of vitamin D. J Am Vet Med Assoc, 184(2):164-170.

LoRusso P, Krishnamurthi S, Rinehart JR, et al. (2005). A Phase 1-2 clinical study of a second generation oral MEK inhibitor, PD0325901 in patients with advanced cancer. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol, 23(16S), abstract 3011.

LoRusso PA, Krishnamurthi SS, Rinehart JJ, et al. (2007). Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapy, abstract B113.

Mansour SJ, Matten WT, Hermann AS, et al. (1994). Transformation of mammalian cells by constitutively active MAP kinase kinase. Science, 265:966-970.

Menon SS, Whitfield LR, Sadis S, et al. (2005). Pharmacokinetics (PK) and pharmacodynamics (PD) of PD0325901, a second generation MEK inhibitor after multiple oral doses of PD0325901 to advanced cancer patients. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol, 23(16S), abstract 3066.

Meuten DJ, Chew DJ, Capen CC, Kociba GJ (1982). Relationship of serum total calcium to albumin and total protein in dogs. J Am Vet Med Assoc, 180:63-67.

Milella M, Kornblau SM, Estrov Z, et al. (2001). Therapeutic targeting of the MEK/ MAPK signal transduction module in acute myeloid leukemia. J Clin Invest, 108(6):851-859.

Morrow C ( 2001 ). Cholecalciferol poisoning. Vet Med, 905 - 911 .

Mortensen JT, Lichtenberg J, Binderup L (1996). Toxicity of 1,25-dihydroxyvitamin D3, tacalcitol, and calcipotriol after topical treatment in rats. J Inv Dermatol Symp Proc, 1:60-63.

Payne RB, Carver ME, Morgan DB (1979). Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol, 32:56-60.

Rinehart J, Adjei AA , LoRusso PM et al. ( 2004 ). Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol, 22(22) :4456-4462.

Roche Laboratories (1998). Package insert, Rocaltrol® (calcitriol) capsules and oral solution. Nov. 20.

Rosenblum IY, Black HE, Ferrell JF (1977). The effects of various diphosphonates on a rat model of cardiac calciphylaxis. Calcif Tissue Res, 23:151-159.

Rosol TJ, Capen CC (1997). Calcium-regulating hormones and diseases of abnormal mineral (calcium, phosphorus, magnesium) metabolism. In Clinical Biochemistry of Domestic Animals, 5th ed. Academic Press, San Diego, CA, pp. 619-702.

Saunders MP, Salisbury AJ, O'Byrne KJ, et al. (1997). A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors. J Clin Endocrinol Metab, 82(12):4044-4048.

Sebolt-Leopold JS, Dudley DT, Herrera R, et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med, 5(7):810-816.

Sebolt-Leopold JS (2000). Development of anticancer drugs targeting the MAP kinase pathway. Oncogene, 19:6594-6599.

Sebolt -Leopold JS, Merriman R , Omer C, ( 2004 ). The biological profile of PD0325901: a second generation analog of CI -1040 with improved pharmaceutical potential . Proc Am Assoc Cancer Res, 45:925 (abstract 4003).

Spangler WL, Gribble DH, Lee TC (1979). Vitamin D intoxication and the pathogenesis of vitamin D nephropathy in the dog. Am J Vet Res, 40:73-83.

Spaulding SW, Walser M (1970). Treatment of experimental hypercalcemia with oral phosphate. J Clin Endocrinol, 31:531-538.

Tan W, DePrimo S, Krishnamurthi SS, et al. (2007). Pharmacokinetic (PK) and pharmacodynamic (PD) results of a phase I study of PD-0325901, a second generation oral MEK inhibitor, in patients with advanced cancer. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapy, abstract B109.

Wang D, Boerner SA, Winkler JD, LoRusso PM (2007). Clinical experience of MEK inhibitors in cancer therapy. Biochimi Biophys Acta, 1773:1248-1255.

York MJ, Evans GO (1996). Electrolyte and fluid balance. In Evans GO (ed.), Animal Clinical Chemistry: A Primer for Toxicologists. Taylor & Francis, New York, pp. 163 - 176 .

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment